Nektar Therapeutics/$NKTR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Ticker
$NKTR
Sector
Primary listing
Employees
61
Headquarters
Website
NKTR Metrics
BasicAdvanced
$1.1B
-
-$8.72
1.07
-
Price and volume
Market cap
$1.1B
Beta
1.07
52-week high
$65.79
52-week low
$7.99
Average daily volume
984K
Financial strength
Current ratio
2.613
Quick ratio
2.464
Long term debt to equity
-639.04
Total debt to equity
-729.953
Interest coverage (TTM)
-5.24%
Profitability
EBITDA (TTM)
-137.165
Gross margin (TTM)
83.44%
Net profit margin (TTM)
-163.17%
Operating margin (TTM)
-185.67%
Effective tax rate (TTM)
0.31%
Revenue per employee (TTM)
$1,230,000
Management effectiveness
Return on assets (TTM)
-31.57%
Return on equity (TTM)
-440.80%
Valuation
Price to revenue (TTM)
11.158
Price to book
-30.68
Price to tangible book (TTM)
-30.68
Price to free cash flow (TTM)
-4.494
Free cash flow yield (TTM)
-22.25%
Free cash flow per share (TTM)
-13.27
Growth
Revenue change (TTM)
-19.56%
Earnings per share change (TTM)
-35.57%
3-year revenue growth (CAGR)
-8.03%
10-year revenue growth (CAGR)
-12.47%
3-year earnings per share growth (CAGR)
-41.00%
10-year earnings per share growth (CAGR)
28.65%
Bulls say / Bears say
Rezpegaldesleukin’s Phase 2b REZOLVE-AD trial achieved both its primary and key secondary endpoints in moderate-to-severe atopic dermatitis, delivering rapid, statistically significant EASI improvements and itch relief at 16 weeks (Investopedia )
The FDA granted Fast Track designation to rezpegaldesleukin for severe-to-very severe alopecia areata, allowing more frequent regulatory interaction and possible rolling review to speed development (RTTNews )
Nektar fully enrolled 84 patients in its REZOLVE-AA Phase 2b study for severe alopecia areata, reducing risk for a key pipeline program and showing strong execution (Investing.com )
GAAP revenue dropped 52% year-over-year to $11.2 million in Q2 2025 after the sale of the Huntsville manufacturing facility, exposing Nektar’s ongoing lack of commercial product income (PRNewswire )
Cash and marketable securities declined from $269.1 million at December 31, 2024 to $175.9 million at June 30, 2025 despite a mid-year equity raise, highlighting significant cash burn even after fundraising (PRNewswire )
R&D expense remained high at $29.9 million in Q2 2025, almost unchanged from $29.7 million in Q2 2024, indicating ongoing heavy development spending with no product approvals to offset costs (PRNewswire )
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
NKTR News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nektar Therapeutics stock?
Nektar Therapeutics (NKTR) has a market cap of $1.1B as of October 30, 2025.
What is the P/E ratio for Nektar Therapeutics stock?
The price to earnings (P/E) ratio for Nektar Therapeutics (NKTR) stock is 0 as of October 30, 2025.
Does Nektar Therapeutics stock pay dividends?
No, Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders as of October 30, 2025.
When is the next Nektar Therapeutics dividend payment date?
Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders.
What is the beta indicator for Nektar Therapeutics?
Nektar Therapeutics (NKTR) has a beta rating of 1.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.